{"id":79908,"date":"2022-12-12T11:01:33","date_gmt":"2022-12-12T10:01:33","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/"},"modified":"2022-12-13T16:00:35","modified_gmt":"2022-12-13T15:00:35","slug":"oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/","title":{"rendered":"Oxolife receives a 2.4M\u20ac grant to develop a new treatment for infertility related to polycystic ovarian syndrome"},"content":{"rendered":"

Oxolife<\/a>, the Women\u2019s Reproductive Health R&D biotech, has been awarded with a 2.4M\u20ac grant from the Spanish Ministry of Science and Innovation<\/a> (within the \u201cPlan Estatal de Investigaci\u00f3n Cient\u00edfica T\u00e9cnica y de Innovaci\u00f3n,<\/em>\u00a0PEICTI<\/a>) to develop a new treatment for infertility related to polycystic ovarian syndrome (PCOS). The company, based in the Barcelona Science Park, plans to progress in the next 2 years from preclinical stages to a phase II clinical trial in PCOS patients in collaboration with University of C\u00f3rdoba (UCO)<\/a>.<\/strong><\/p>\n

PCOS is an endocrine disease affecting up to 13% of women of childbearing age, causing infertility in most of them (>70%). Unfortunately, current medical management, based on restoring ovulatory function or metabolic status, cannot meet the expectations of women and couples, since more than 60% cannot become pregnant with available treatments.<\/p>\n

Oxolife<\/a> is developing a unique new treatment designed to restore the reproductive system in a single intervention, with the potential to overcome the limitations of current strategies in PCOS.<\/p>\n

Ignasi Canals<\/strong>, Oxolife\u2019s CSO, explains: “This grant speeds up a promising line of research that targets ovarian dysfunction, endometrial receptivity, and the metabolic status, tackling the syndrome in a holistic way. We\u2019re encouraged to provide a solution for women and couples suffering from PCOS, in a short period”.<\/p>\n

With its pipeline, Oxolife, achieves a prominent position within the Women’s Reproductive Health biotech sector.<\/p>\n

Oxolife\u2019s CEO and CMO, Agnes Arbat<\/strong>, declares: \u201cWith a pharmaceutical compound that increases embryo implantation already in phase II human trials, and a unique late-stage preclinical asset for infertility related to PCOS, we cover the most prevalent causes of female infertility. We\u2019re now in a privileged position, enlarging the pipeline and transferring projects from early stages to late development of consistent and convenient products, bringing new solutions to patients\u201d.<\/p>\n

\u00bb Related news [+]<\/a><\/strong><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Oxolife, the Women\u2019s Reproductive Health R&D biotech, has been awarded with a 2.4M\u20ac grant from the Spanish Ministry of Science and Innovation (within the \u201cPlan Estatal de Investigaci\u00f3n Cient\u00edfica T\u00e9cnica…<\/p>\n","protected":false},"author":11,"featured_media":79902,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-79908","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business"],"acf":[],"yoast_head":"\nOxolife receives a 2.4M\u20ac grant to develop a new treatment for infertility related to polycystic ovarian syndrome - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oxolife receives a 2.4M\u20ac grant to develop a new treatment for infertility related to polycystic ovarian syndrome - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Oxolife, the Women\u2019s Reproductive Health R&D biotech, has been awarded with a 2.4M\u20ac grant from the Spanish Ministry of Science and Innovation (within the \u201cPlan Estatal de Investigaci\u00f3n Cient\u00edfica T\u00e9cnica...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-12T10:01:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-13T15:00:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/oxolife-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Iuris\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Iuris\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/\"},\"author\":{\"name\":\"Iuris\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/2cac99ef7339e3499496b54bb2e12e7d\"},\"headline\":\"Oxolife receives a 2.4M\u20ac grant to develop a new treatment for infertility related to polycystic ovarian syndrome\",\"datePublished\":\"2022-12-12T10:01:33+00:00\",\"dateModified\":\"2022-12-13T15:00:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/\"},\"wordCount\":323,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/oxolife-1.jpg\",\"articleSection\":[\"COMPANIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/\",\"name\":\"Oxolife receives a 2.4M\u20ac grant to develop a new treatment for infertility related to polycystic ovarian syndrome - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/oxolife-1.jpg\",\"datePublished\":\"2022-12-12T10:01:33+00:00\",\"dateModified\":\"2022-12-13T15:00:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/2cac99ef7339e3499496b54bb2e12e7d\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/oxolife-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/oxolife-1.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oxolife receives a 2.4M\u20ac grant to develop a new treatment for infertility related to polycystic ovarian syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/2cac99ef7339e3499496b54bb2e12e7d\",\"name\":\"Iuris\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g\",\"caption\":\"Iuris\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminiuris\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oxolife receives a 2.4M\u20ac grant to develop a new treatment for infertility related to polycystic ovarian syndrome - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"Oxolife receives a 2.4M\u20ac grant to develop a new treatment for infertility related to polycystic ovarian syndrome - Parc Cient\u00edfic de Barcelona","og_description":"Oxolife, the Women\u2019s Reproductive Health R&D biotech, has been awarded with a 2.4M\u20ac grant from the Spanish Ministry of Science and Innovation (within the \u201cPlan Estatal de Investigaci\u00f3n Cient\u00edfica T\u00e9cnica...","og_url":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2022-12-12T10:01:33+00:00","article_modified_time":"2022-12-13T15:00:35+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/oxolife-1.jpg","type":"image\/jpeg"}],"author":"Iuris","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Iuris","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/"},"author":{"name":"Iuris","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d"},"headline":"Oxolife receives a 2.4M\u20ac grant to develop a new treatment for infertility related to polycystic ovarian syndrome","datePublished":"2022-12-12T10:01:33+00:00","dateModified":"2022-12-13T15:00:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/"},"wordCount":323,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/oxolife-1.jpg","articleSection":["COMPANIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/","url":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/","name":"Oxolife receives a 2.4M\u20ac grant to develop a new treatment for infertility related to polycystic ovarian syndrome - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/oxolife-1.jpg","datePublished":"2022-12-12T10:01:33+00:00","dateModified":"2022-12-13T15:00:35+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/oxolife-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/12\/oxolife-1.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/oxolife-receives-a-2-4me-grant-to-develop-a-new-treatment-for-infertility-related-to-polycystic-ovarian-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Oxolife receives a 2.4M\u20ac grant to develop a new treatment for infertility related to polycystic ovarian syndrome"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/2cac99ef7339e3499496b54bb2e12e7d","name":"Iuris","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a9d1bfedf501cbd8ae27b11de9986604bf4cdcea73b507457dfd4ff5dc770b75?s=96&d=mm&r=g","caption":"Iuris"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminiuris\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/79908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=79908"}],"version-history":[{"count":7,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/79908\/revisions"}],"predecessor-version":[{"id":79970,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/79908\/revisions\/79970"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/79902"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=79908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=79908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=79908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}